HeraMED Ltd (ASX: HMD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

HeraMED Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $49.61 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 177.19 million
Earnings per share -0.025
Dividend per share N/A
Year To Date Return 154.55%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

HeraMED Ltd (ASX: HMD)
Latest News

HMD ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About HeraMED Ltd

HeraMED Ltd is engaged in developing innovative, connected pregnancy monitoring solutions for home and professional use. It has developed a foetal heart beat monitor called HeraBEAT which is a medical-grade, clinically-validated, smart andconnected Ultrasound Foetal Doppler device predominantly for use by an expectant mother to self-monitor her foetus' heart rate (FHR).

HMD Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
02 Dec 2021 $0.28 $0.00 0.00% 459,882 $0.28 $0.29 $0.27
01 Dec 2021 $0.28 $0.01 3.64% 175,214 $0.27 $0.28 $0.27
30 Nov 2021 $0.28 $0.01 3.70% 208,460 $0.28 $0.29 $0.28
29 Nov 2021 $0.27 $-0.03 -10.17% 797,310 $0.29 $0.29 $0.27
26 Nov 2021 $0.30 $-0.02 -6.45% 115,279 $0.31 $0.31 $0.29
25 Nov 2021 $0.31 $0.01 3.28% 394,379 $0.30 $0.31 $0.30
24 Nov 2021 $0.31 $-0.01 -3.23% 623,387 $0.31 $0.32 $0.30
23 Nov 2021 $0.31 $-0.01 -3.13% 957,843 $0.33 $0.33 $0.31
22 Nov 2021 $0.32 $0.02 6.67% 953,560 $0.31 $0.34 $0.31
19 Nov 2021 $0.30 $-0.02 -6.35% 403,334 $0.32 $0.32 $0.30
18 Nov 2021 $0.32 $0.00 0.00% 1,047,020 $0.30 $0.32 $0.29
17 Nov 2021 $0.32 $0.06 23.08% 2,306,844 $0.27 $0.34 $0.27
16 Nov 2021 $0.26 $-0.02 -7.14% 1,065,034 $0.27 $0.29 $0.26
15 Nov 2021 $0.28 $0.02 7.55% 1,435,117 $0.28 $0.32 $0.27
12 Nov 2021 $0.27 $0.04 17.78% 1,558,733 $0.22 $0.27 $0.22
11 Nov 2021 $0.23 $0.04 21.05% 1,602,391 $0.20 $0.23 $0.20
10 Nov 2021 $0.19 $-0.01 -5.00% 57,094 $0.20 $0.20 $0.19
09 Nov 2021 $0.20 $0.01 5.13% 447,517 $0.20 $0.20 $0.19
08 Nov 2021 $0.20 $0.00 0.00% 396,140 $0.20 $0.21 $0.20
05 Nov 2021 $0.20 $-0.01 -4.88% 358,704 $0.21 $0.21 $0.20
04 Nov 2021 $0.21 $0.00 0.00% 230,593 $0.20 $0.21 $0.20
03 Nov 2021 $0.20 $0.00 0.00% 243,739 $0.20 $0.20 $0.20

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr David Hinton Non-Executive Director Aug 2018
Mr Hinton has an career in the information and technology sectors and is currently Chief Financial Officer and Company Secretary of Empired Limited, an ASX listed IT and software services provider and prior to that Amcom Telecommunications Ltd. Mr Hinton is also a Director of Auspire - The Australia Day Council of Western Australia.
Dr Ronald (Ron) Peter Weinberger Non-Executive ChairmanNon-Executive Director Aug 2018
Dr Weinberger is an experienced technology and business development executive, with a demonstrated history of building significant value at multiple levels in the medical device industry. During his time at Nanosonics, he co-developed their platform technology, launched their breakthrough product Trophon globally and created North American sales team to work alongside GE Healthcare. He also developed the distribution strategy for Europe having partnered with Toshiba Medical Systems (now Canon Medical Systems) and Miele Professional.
Mr Doron Birger Non-Executive Director Oct 2018
Mr Birger is the former Chairman of Given Imaging (NASDAQ/TASE:GIVN), CEO of Elron electronic industries (Nasdaq/TASE: ELRN) and was a board member, during different periods, in a variety of publicly traded companies. During such period, he was involved in investments, merger and acquisitions, exits, public offerings on NASDAQ and TASE and private equity rounds totalling billions of dollars. Mr Birger currently serves as chairman and board member and consultant to a variety of technology companies, mainly in the medical device field, and conducts many voluntary and public activities. He was also Chairman of Medigus LTD and Insuline. He was also director of MCS MEDICAL, HBL Hadasit and Icecure.
Mr David Groberman Chief Executive OfficerExecutive Director Sep 2018
Mr Groberman is a mechanical and bio-medical engineer with over 17 years of experience in developing multi-disciplinary medical technologies across a wide spectrum of the industry. He spent over 8 years as co-founder and Chief Technology Officer at Meytar R&D - one of the leading service provide firms in Israel. During his time with Meytar R&D, he gained, hands-on knowledge and capabilities, leading some of the most challenging projects in the field of multi-disciplinary medical and high-tech devices, ranging from implants to invasive mechanical, electro-mechanical and opto-mechanical instruments, surgical apparatuses and applicators, monitoring, diagnosis and scanning equipment.
Mr Tal Slonim Chief Operating OfficerExecutive Director Sep 2018
Mr Slonim is a qualified engineer and operations manager with over 22 years of experience. He is the co-founder and part-time CEO of Meytar R&D, one of Israel's top R&D services firm. Mr Slonim brings vast knowledge, hands-on capabilities and profound experience in system design of multi-disciplinary, integrated solutions as well as transition to mass manufacturing and production line erection and validation.
Mr Jonathan Hart Company Secretary Mar 2020
-
Jonathan Hart Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Altshuler Shaham Trusts Ltd (Holley Pharma Co Ltd A/C) 10,857,385 6.17%
Altor Capital Management Pty Ltd (Altor Alpha Fund A/C) 10,853,467 6.17%
Altshuler Shaham Trusts Ltd (David Groberman A/C) 9,245,418 5.25%
Altshuler Shaham Trusts Ltd (Tal Slonim A/C) 9,245,418 5.25%
Freeman Road Pty Ltd (The Avenue A/C) 6,912,365 3.93%
Citicorp Nominees Pty Limited 5,713,618 3.25%
Etchell Capital Ltd 3,512,500 2.00%
HSBC Custody Nominees (Australia) Limited 3,511,142 2.00%
Altshuler Shaham Trusts Ltd (Michael Nenner A/C) 3,040,774 1.73%
Chris Ntoumenopoulos 3,025,000 1.72%
Mayo Clinic 2,767,691 1.57%
Pula Holdings Pty Ltd (Herath Super Fund A/C) 2,019,000 1.15%
Mrs Amandeep Kaur 1,850,000 1.05%
Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) 1,591,586 0.90%
Cardup Syndicate Holdings Pty Ltd (The Cardup Syndicate A/C) 1,533,750 0.87%
Dr Matthew Farrugia 1,394,739 0.79%
Mr Barry John Ashwin & Dr Desiree Silva 1,388,833 0.79%
Sobol Capital Pty Ltd (Boc A/C) 1,305,555 0.74%
S & S Browne Assets Pty Ltd (S & S Browne Investment A/C) 1,225,000 0.70%
J P Morgan Nominees Australia Pty Limited 1,090,949 0.62%

Profile

since

Note